bioAffinity Technologies secures Hong Kong patent for CyPath lung cancer diagnostic. Hong Kong patent grant for CyPath adds regional IP protection that may support Asian market expansion.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 2.82 | 1.11 | 6.45 | 2.43 |
| Receivables | 0.81 | 1.14 | 0.54 | 0.89 |
| Inventory | 0.02 | 0.03 | 0.05 | 0.08 |
| Other | — | — | — | — |
| 3.97 | 2.70 | 7.57 | 3.87 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.60 | 0.99 | 0.76 | 0.97 |
| ST’ Debt | — | 0.17 | 0.11 | 0.02 |
| Other | — | — | — | — |
| 2.25 | 3.10 | 2.91 | 2.68 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 1.35 | 1.51 | — | — |
—
|
| ’25 | 1.85 | 1.27 | 1.45 | 1.59 |
6.16
|
| ’24 | 2.41 | 2.40 | 2.35 | 2.21 |
9.36
|
| ’23 | 0.00 | 0.02 | 0.30 | 2.21 |
2.53
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.23) | (3.20) | — | — |
—
|
| ’25 | (1.64) | (2.65) | (2.48) | (2.56) |
(9.33)
|
| ’24 | (2.35) | (1.53) | (1.71) | (1.68) |
(7.26)
|
| ’23 | (1.53) | (1.36) | (1.53) | (1.62) |
(6.04)
|
| ’22 | (0.63) | (0.38) | (1.76) | (1.30) |
(4.07)
|
| ’21 | — | — | (1.40) | (0.65) |
(2.05)
|
| ’20 | — | — | — | — |
(2.21)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.23) | (3.29) | — | — |
—
|
| ’25 | (1.69) | (2.66) | (2.48) | (2.56) |
(9.39)
|
| ’24 | (2.39) | (1.56) | (1.72) | (1.68) |
(7.34)
|
| ’23 | (1.56) | (1.36) | (1.53) | (1.60) |
(6.06)
|
| ’22 | (0.63) | (0.38) | (1.76) | (1.52) |
(4.29)
|
| ’21 | — | — | (1.40) | (0.65) |
(2.05)
|
| ’20 | — | — | — | — |
(2.21)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (12.14) | (9.60) | — | — |
—
|
| ’25 | (72.04) | (76.54) | (71.06) | (16.64) |
(129.84)
|
| ’24 | (94.55) | (85.54) | (72.04) | (94.55) |
(337.68)
|
| ’23 | (81.04) | (90.04) | (117.06) | (117.06) |
(409.70)
|
| ’22 | — | — | (495.25) | (0.20) |
(814.90)
|
| ’21 | — | — | — | — |
(1.06k)
|
| ’20 | — | — | — | — |
(0.99)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 589.50 | 429.75 | 373.95 | 16.65 | — | — | — |
Low Price
|
| — | — | — | — | — | — | 6,997.50 | 1,795.50 | 1,629.00 | 697.95 | — | — | — |
High Price
|
| — | — | — | — | — | ‡‡‡‡ | 14 | 75 | 57 | 57 | — | — | — |
Employees
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.03 | 0.16 | 0.11 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | 0.00 | 2.53 | 9.36 | 6.16 | ‡‡‡‡‡ | — | — |
Revenue
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 89.58% | 31.26% | 36.09% | 31.41% | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.15) | (7.92) | (9.03) | (14.87) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | (169,827.08%) | (312.58%) | (96.43%) | (241.25%) | ‡‡‡ | — | — |
EBT Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.15) | (7.94) | (9.04) | (14.91) | ‡‡‡‡‡ | — | — |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.07 | 0.25 | 0.61 | 0.50 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.48 | 130.54 | 346.74 | 53.68 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (814.90) | (409.70) | (337.68) | (129.84) | ‡‡‡‡ | — | — |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (407.08) | (311.23) | (269.07) | (81.26) | — | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | (22.00) | (1.18) | (2.93) | (0.53) | ‡‡‡ | — | — |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (429.08) | (312.41) | (272.00) | (81.79) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,104.34 | 250.27 | 96.37 | 63.39 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.01 | 0.02 | 0.03 | 0.11 | ‡‡‡‡‡ | — | — |
Shares
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | — | — |
PE Ratio
|
| — | — | — | — | — | — | 0.00 | 5.83 | 1.18 | 0.33 | ‡‡‡ | — | — |
PS Ratio
|
| — | — | — | — | — | — | 0.64 | 3.04 | 4.25 | 0.28 | ‡‡‡ | — | — |
PB Ratio
|
| — | — | — | — | — | — | 0.00 | 5.22 | 1.13 | (0.61) | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | — | — | 1.02 | (2.18) | (1.44) | 0.40 | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.07) | (6.04) | (7.26) | (9.33) | ‡‡‡ | — | — |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — | (0.22) | (0.02) | (0.08) | (0.06) | — | — | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.29) | (6.06) | (7.34) | (9.39) | — | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.82 | 1.72 | (0.41) | 4.66 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.25 | 0.84 | 0.64 | 0.68 | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.16) | (1.99) | (0.47) | (5.77) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.04 | 4.86 | 2.60 | 7.28 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (119.60%) | (77.80%) | (122.70%) | (170.65%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | (173.68%) | (262.35%) | (438.42%) | — | — | — |
ROIC
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 343.53% | (99.84%) | (242.44%) | (301.83%) | — | — | — |
ROE
|
bioAffinity Technologies (BIAF), a clinical-stage biotech specializing in non-invasive cancer diagnostics like CyPath Lung, has delivered explosive revenue growth—from $4,800 in 2022 to $9.36 million in 2024—post-SPAC merger, signaling strong commercialization momentum and efficiency gains with revenue per employee surging 386%. Yet, this topline shine masks severe risks: eroding gross margins, deepening losses with EBT at -$9.03 million and ROE cratering to -242% in 2024, relentless cash burn, and massive share dilution projected to balloon shares over 1,000% by 2026, threatening book value.
The balance sheet shows deleveraging with debt slashed 94% and net cash positive, but working capital turned negative, amplifying liquidity strains amid volatile stock swings—down 99% from 2022 peaks despite revenue ramps. Analyst consensus dangles a staggering 17,000% upside, fueled by hopes for diagnostic adoption akin to Guardant Health, but forecasts flag 2025 revenue contraction and widening net losses, with zero insider buying underscoring caution in a funding-winter biotech landscape.
This high-reward speculative play tempts with revenue potential against a downside skew of execution pitfalls, dilution, and unproven profitability—demanding rigorous scrutiny for investors eyeing lottery-like returns.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.